Month: August 2020

BRIDGEWATER, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging, digital and IoT platforms, today announced it has secured a renewal to its agreement to provide Verizon with its White-Label Personal Cloud Platform. The deal will enable Verizon to provide secure, easy-to-use cloud storage for customers and safely protect their valuable personal digital content, including photos, videos and messages.“We are thrilled to further extend our long-standing relationship with Verizon to help deliver a successful, much-desired personal cloud service to its customers for many years to come,” said Glenn Lurie, President and CEO at Synchronoss. “Today’s devices are a key repository for much of our digital content, from family photos and videos to contacts, documents,...

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver liquidity, execution services and analytics and connectivity products, today announced the appointment of Sean P. Galvin as its new Chief Financial Officer along with the promotions of Cindy Lee as its Deputy Chief Financial Officer and Colm Mac Curtain as its Head of Finance EMEA.“We are pleased to announce Sean’s return to Virtu in the Chief Financial Officer role.  Sean’s deep knowledge of our business and industry along with his financial and leadership acumen will add significant value to Virtu,” said Virtu’s Chief Executive Officer, Douglas A. Cifu.  “Cindy’s expertise has contributed significantly to the Company through its growth and maturation...

DAYTONA BEACH, Fla., Aug. 10, 2020 (GLOBE NEWSWIRE) — TopBuild Corp. (NYSE:BLD), a leading installer and distributor of insulation and building material products to the U.S. construction industry, announced that Luis F. Machado has joined the Company as General Counsel and Corporate Secretary. Jerry Volas, Chief Executive Officer, stated, “We are pleased to welcome Luis to TopBuild.  He brings more than twenty years of experience leading legal and compliance functions across a wide range of industries.  He is a terrific addition to our senior leadership team.”Prior to joining TopBuild, Machado served as Vice President, General Counsel and Secretary for CTS Corporation, a global leader in the design and manufacturing of sensors, actuators, and electronic components. He has also served in senior corporate legal positions at L Brands,...

DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2020, and provided an overview of recent operational highlights.“We have made solid progress over the past few months towards our core mandate of developing important new therapies for patients suffering from underserved rare and near rare neuropsychiatric disorders,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “Regarding our pivotal CONNECT-FX data in Fragile X Syndrome, we continue to evaluate the data and believe that we have identified an important and severely impacted patient population that responded well...

PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONEREGULATORY UPDATE ON OMAVELOXOLONEYEAR 2 DATA FROM CARDINAL TRIAL EXPECTED IN FOURTH QUARTER 2020ENROLLMENT RESUMED IN FALCON TRIALPLANO, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended June 30, 2020, and provided an update on the Company’s business operations and clinical development programs.Regulatory UpdateBardoxolone Methyl (“Bardoxolone”) for Alport SyndromeSince the announcement of positive, Year 1 data from the Phase 3 CARDINAL study, we have been engaged in discussions with the U.S. Food and Drug Administration (“FDA”) regarding the Year 1 efficacy and safety results.  We have had a Type C meeting...

DLR gennemfører auktioner over rentetilpasningsobligationer i DKK den 18. og 19. august 2020.Grundlaget for auktionerne vil være særligt dækkede obligationer (SDO), som DLR udsteder til brug for refinansiering af rentetilpasningslån pr. 1. oktober 2020.Vilkår for auktionerne, udbudte mængder samt auktionstidspunkter fremgår af vedhæftede fil. Henvendelse kan rettes til fondschef Erik Bladt på telefon 33 42 07 37. Med venlig hilsenDLR Kredit A/SVedhæftet filVilkår og mængder – refinansieringsauktion oktober termin

– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –– Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –– Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .“We’re pleased to announce our plans for developing LB-001 in pediatric patients with MMA. This is an important milestone for patients, their families, our company and...

OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesicOLINVYK product availability expected in fourth quarter of 2020Company funded through year-end 2021, including OLINVYK commercialization—Company to host conference call at 8:30 a.m., today, August 10, 2020—CHESTERBROOK, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved OLINVYK in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will be...

Reports second-quarter revenues of $57.4 million; adjusted EBITDA of $7.4 million, both exceeding guidanceReports net income of $0.6 million; GAAP EPS of $0.01; adjusted EPS of $0.06Delivers record quarterly cash flow from operating activities of $22 million; generates $47 million of cash flow from operating activities over the last twelve monthsReports quarter-end cash balance of $32 millionReduces debt balance by a further 7%, or $6 millionAcquires intelligent automation firm Neuralify; fully merges it with ISG AutomationSets third-quarter 2020 guidance: revenues of between $53 million and $55 million and adjusted EBITDA of between $6 million and $7 millionSTAMFORD, Conn., Aug. 10, 2020 (GLOBE NEWSWIRE) — Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, today announced financial...

TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards.As previously disclosed, on August 14, 2019, the Company received a Deficiency Letter from the NYSE American stating that InspireMD was not in compliance with certain NYSE American continued listing standards relating to stockholders’ equity. Specifically, InspireMD was not in compliance with Part 10, Section 1003(a)(iii) of the NYSE American Company Guide, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses...